Gout

At least 65% of rheumatologists at Veterans Affairs facilities view telemedicine as appropriate for established patients with gout, stable rheumatoid arthritis, osteoarthritis, stable spondyloarthritis and other diseases, researchers noted.

Psoriatic arthritis and gout often present with similar symptoms and radiological signs, an overlap that may be more significant when these diseases occur concomitantly, noted a presenter at the 2020 Congress of Clinical Rheumatology-West.

An increased proportion of patients with uncontrolled gout maintained treatment response at 6 months with concomitant methotrexate and pegloticase, compared with pegloticase alone, according to data published in The Journal of Rheumatology.

Research presented at the virtual American Heart Association Hypertension Scientific Session showed that BP control dropped more than 11% in the United States from 2013 to 2018. It was the top story in cardiology last week.

New and emerging risk stratification tools can assist rheumatologists who are increasingly “taking on the challenge” of cardiovascular risk management in patients, according to a speaker at the 2020 Congress of Clinical Rheumatology-East.

While the 2020 American College of Rheumatology guidelines for gout management are a step up from the 2012 iteration, gaps remain in management of the disease, according to a presenter at the 2020 Congress of Clinical Rheumatology-East.

In a substudy of the COLCOT trial, patients with MI benefited the most from colchicine if it was initiated early in their hospital stay, according to data presented at the virtual European Society of Cardiology Congress.

The burden of gout increased around the world from 1990 to 2017, with a total prevalent case count of 41.2 million, and 1.3 million years lived with disability, estimated for 2017, according to data published in Arthritis & Rheumatology.

In patients with chronic coronary disease, adding low-dose colchicine to optimal medical therapy reduced risk for CV events by 31%, according to results of the LoDoCo2 trial presented at the European Society of Cardiology Congress.

Among patients with gout, ultrasound scoring for crystal deposits demonstrates that treat-to-target with urate-lowering therapy results in significant reductions in all depositions, according to data published in the Annals of the Rheumatic Diseases.